---
title: "和黃醫藥盤前跌逾 2% 大摩首予 “賣出” 評級"
description: "和黃醫藥盤前跌 2.58%，報 16.6 美元。消息面上，摩根士丹利分析師 Jack Lin 首予和黃醫藥 “賣出” 評級，目標價 13.75 美元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/258318904.md"
published_at: "2025-09-22T09:43:21.000Z"
---

# 和黃醫藥盤前跌逾 2% 大摩首予 “賣出” 評級

> 和黃醫藥盤前跌 2.58%，報 16.6 美元。消息面上，摩根士丹利分析師 Jack Lin 首予和黃醫藥 “賣出” 評級，目標價 13.75 美元。

和黃醫藥盤前跌 2.58%，報 16.6 美元。消息面上，摩根士丹利分析師 Jack Lin 首予和黃醫藥 “賣出” 評級，目標價 13.75 美元。

### Related Stocks

- [HCM.US - 和黃醫藥](https://longbridge.com/zh-HK/quote/HCM.US.md)
- [00013.HK - 和黃醫藥](https://longbridge.com/zh-HK/quote/00013.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hutchmed China hails lung cancer trial results published in Lancet | Hutchmed China Ltd announced that results from its SACHI phase-three lung cancer trial have been published in The Lancet | [Link](https://longbridge.com/zh-HK/news/272549848.md) |
| HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event | - HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanis | [Link](https://longbridge.com/zh-HK/news/263921874.md) |
| Anthropic: Investors in round include Insight Partners, Jane Street, JPMorganChase through Security & Resiliency Initiative & Growth Equity Partners | Anthropic: Investors in round include Insight Partners, Jane Street, JPMorganChase through Security & Resiliency Initiat | [Link](https://longbridge.com/zh-HK/news/275799043.md) |
| West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives | West Pharmaceutical Services reported Q3 FY 2025 revenue of $804.6 million and EPS of $1.94, showing a revenue increase  | [Link](https://longbridge.com/zh-HK/news/275848079.md) |
| These Analysts Increase Their Forecasts On Equinix Following Q4 Results | Equinix Inc (NASDAQ:EQIX) reported strong Q4 results with FFO of $8.91 per share, exceeding estimates. However, quarterl | [Link](https://longbridge.com/zh-HK/news/275783781.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。